AbbVie Inc. (ABBV) Performance:23.10%(TTM)
The total return for AbbVie Inc. (ABBV) stock is +23.10% over the past 12 months vs. +24.34% for the S&P 500. So far it's up +0.28% this year. Includes price appreciation + reinvested dividends.
AbbVie Inc. (ABBV) Compound Annual Growth Rates (CAGR) Summary
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +19.18% | +17.72% | +14.61% | +14.01% | - | - |
| Total Return CAGR | +23.10% | +22.04% | +19.01% | +18.82% | - | - |
| Revenue CAGR | +9.51% | +3.45% | +4.59% | +10.20% | - | - |
| Net Income CAGR | (13.26%) | (21.71%) | (6.74%) | (4.00%) | - | - |
| EPS CAGR | (1.25%) | (29.10%) | (2.79%) | (2.80%) | (0.59%) | - |
| Free Cash Flow CAGR | +35.65% | (3.91%) | +3.24% | +10.67% | - | - |
| Operating Cash Flow CAGR | +29.43% | (4.32%) | +2.62% | +10.14% | - | - |
| Dividends CAGR | +5.81% | +5.16% | +6.81% | +12.50% | - | - |
CAGR Trends History
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
ABBV Total Return CAGR Chart
AbbVie Inc. (ABBV)
Annual Total Returns Comparison
| Year | Start Value | End Value | ABBV Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | 1098.86 | 1101.92 | +0.28% | +8.38% | (8.10%) |
| 2025 | 825.42 | 1098.86 | +33.13% | +17.72% | +15.41% |
| 2024 | 694.22 | 825.42 | +18.90% | +24.89% | (5.99%) |
| 2023 | 695.80 | 694.22 | (0.23%) | +26.19% | (26.42%) |
| 2022 | 560.95 | 695.80 | +24.04% | (18.17%) | +42.21% |
| 2021 | 423.68 | 560.95 | +32.40% | +28.74% | +3.66% |
| 2020 | 332.01 | 423.68 | +27.61% | +18.37% | +9.24% |
| 2019 | 327.11 | 332.01 | +1.50% | +31.22% | (29.72%) |
| 2018 | 330.35 | 327.11 | (0.98%) | (4.56%) | +3.58% |
| 2017 | 206.30 | 330.35 | +60.13% | +21.70% | +38.43% |
About AbbVie Inc.
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert A. Michael